KROS insider buying – Keros Therapeutics, Inc.
13 insider purchases since 2016 worth $27.8M by 8 different insiders. Last 12 months: 6 purchases, $75,770. Most recent filing: 2026-08-19.
Mid company Public float $453M (latest 10-K, SEC).
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits. 6 older purchases (before the 5-year window) are listed in the table below.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| ADAR1 Partners, LP 10% Owner | $9.5M 1× · 934,258 sh | 2025-04-09 2025-04-09 | – | 5,390,964 shares as of 2025-04-11 | Holds - never sold |
| Kariv Tomer Director | $7.0M 1× · 437,499 sh | 2020-04-13 2020-04-13 | – | 155,262 shares as of 2025-06-11 | Holds - never sold |
| GORDON CARL L Director | $6.0M 1× · 375,200 sh | 2020-04-13 2020-04-13 | – | 759,155 shares as of 2025-12-18 | Holds - never sold |
| Pontifax Late Stage Fund L.P. 10% Owner | $3.0M 1× · 60,000 sh | 2020-11-17 2020-11-17 | – | 2,288,151 shares as of 2020-11-19 | Holds - never sold |
| Arkin Bio Venture Partners Ltd. 10% Owner | $1.9M 1× · 120,000 sh | 2020-04-13 2020-04-13 | – | 1,382,295 shares as of 2020-04-13 | Holds - never sold |
| Seehra Jasbir CEO | $320,000 1× · 20,000 sh | 2020-04-13 2020-04-13 | 1× · $113,433 last 2026-02-19 | 440,708 shares as of 2026-04-06 | Sold part |
| BIENAIME JEAN JACQUES Director | $75,770 6× · 7,000 sh | 2026-03-09 2026-08-17 | – | 19,592 shares as of 2026-08-19 | Holds - never sold |
| Knowles Julius Director | $24,987 1× · 1,191 sh | 2020-04-13 2020-04-13 | 17× · $28.8M last 2022-01-03 | 113,191 shares as of 2026-06-08 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 6 | $75,770 | 1 | 4 | $331,821 |
| 2025 | 1 | $9.5M | 1 | 2 | $180.6M |
| 2024 | 0 | – | – | 2 | $12.8M |
| 2023 | 1 | $24,987 | 1 | 1 | $1.9M |
| 2022 | 0 | – | – | 11 | $5.9M |
| 2021 | 0 | – | – | 29 | $29.5M |
| 2020 | 5 | $18.2M | 5 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | BIENAIME JEAN JACQUES | Director | 1,000 | $10.27 | $10,270 | +5.4% | SEC |
| 2026-07-17 | BIENAIME JEAN JACQUES | Director | 1,000 | $10.61 | $10,610 | +5.7% | SEC |
| 2026-06-17 | BIENAIME JEAN JACQUES | Director | 1,000 | $10.19 | $10,190 | +6.0% | SEC |
| 2026-05-19 | BIENAIME JEAN JACQUES | Director | 1,000 | $10.58 | $10,580 | +11.8% | SEC |
| 2026-04-17 | BIENAIME JEAN JACQUES | Director | 1,000 | $11.70 | $11,700 | +13.4% | SEC |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | 2,000 | $11.21 | $22,420 | +36.7% | SEC |
| 2025-04-11 | ADAR1 Partners, LP | 10% Owner | 934,258 | $10.13 | $9.5M | +27.0% | SEC |
| 2023-01-20 | Knowles Julius | Director | 1,191 | $20.98 | $24,987 | SEC | |
| 2020-11-19 | Pontifax Late Stage Fund L.P. | 10% Owner | 60,000 | $50.00 | $3.0M | +2.7% | SEC |
| 2020-04-13 | Seehra Jasbir | CEO | 20,000 | $16.00 | $320,000 | +8.9% | SEC |
| 2020-04-13 | Kariv Tomer | Director | 437,499 | $16.00 | $7.0M | +24.0% | SEC |
| 2020-04-13 | GORDON CARL L | Director | 375,200 | $16.00 | $6.0M | +50.4% | SEC |
| 2020-04-13 | Arkin Bio Venture Partners Ltd. | 10% Owner | 120,000 | $16.00 | $1.9M | +6.3% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-20 | Seehra Jasbir | CEO | 7,015 | $16.17 | $113,433 | Sale | SEC |
| 2026-02-20 | Regnante Keith | CFO | 4,739 | $16.35 | $77,483 | Sale | SEC |
| 2026-02-20 | Lerner Lorena Raquel | Officer | 3,873 | $16.35 | $63,324 | Sale | SEC |
| 2026-02-20 | Cho Esther | Officer | 4,745 | $16.35 | $77,581 | Sale | SEC |
| 2025-10-17 | Pontifax (China) IV L.P. | Director | 4,787,331 | $17.75 | $85.0M | Sale | SEC |
| 2025-10-15 | Schneeberger Daniel | 10% Owner | 5,389,264 | $17.75 | $95.7M | Sale | SEC |
| 2024-08-15 | OrbiMed Genesis GP LLC | Director | 250,000 | $44.01 | $11.0M | Sale | SEC |
| 2024-01-08 | Regnante Keith | CFO | 40,000 | $45.29 | $1.8M | Sale | SEC |
| 2023-06-12 | Regnante Keith | CFO | 40,000 | $46.61 | $1.9M | Pre-planned (10b5-1) | SEC |
| 2022-07-19 | Lachey Jennifer | Officer | 46,034 | $30.00 | $1.4M | Sale | SEC |
| 2022-07-15 | Lachey Jennifer | Officer | 1,916 | $30.00 | $57,480 | Sale | SEC |
| 2022-05-13 | Lachey Jennifer | Officer | 5,300 | $41.90 | $222,050 | Sale | SEC |
| 2022-04-13 | Lachey Jennifer | Officer | 5,300 | $62.77 | $332,705 | Sale | SEC |
| 2022-04-08 | Rovaldi Christopher | Officer | 1,728 | $65.00 | $112,320 | Sale | SEC |
| 2022-04-06 | Lachey Jennifer | Officer | 7,950 | $60.00 | $477,000 | Sale | SEC |
Showing the latest 15 of 49 sales of $50,000+ since 2016.
Recent company events (SEC 8-K)
- 2026-11-05 - Quarterly results released (SEC)
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free